Ignite Creation Date:
2025-12-24 @ 1:36 PM
Ignite Modification Date:
2026-04-23 @ 8:05 AM
Study NCT ID:
NCT03092895
Status:
COMPLETED
Last Update Posted:
2023-02-08
First Post:
2017-03-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'submissionInfos': [{'resetDate': '2024-02-16', 'releaseDate': '2023-07-04'}, {'resetDate': '2024-08-16', 'releaseDate': '2024-03-22'}], 'estimatedResultsFirstSubmitDate': '2023-07-04'}}, 'interventionBrowseModule': {'meshes': [{'id': 'C000631724', 'term': 'camrelizumab'}, {'id': 'C553458', 'term': 'apatinib'}, {'id': 'C410216', 'term': 'Folfox protocol'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 157}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-04-27', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-04', 'completionDateStruct': {'date': '2021-03-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-02-06', 'studyFirstSubmitDate': '2017-03-15', 'studyFirstSubmitQcDate': '2017-03-22', 'lastUpdatePostDateStruct': {'date': '2023-02-08', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-03-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-03-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The safety and tolerability', 'timeFrame': 'Up to approximately 2years', 'description': 'The incidence and grade of adverse events (AEs) and Serious adverse events (SAEs) assessed by NCI-CTCAE v4.03'}], 'secondaryOutcomes': [{'measure': 'Objective Response Rate (ORR)', 'timeFrame': 'Up to approximately 2 years', 'description': 'Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)'}, {'measure': 'Duration of Response (DoR)', 'timeFrame': 'Up to approximately 2 years', 'description': 'Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)'}, {'measure': 'Disease Control Rate (DCR)', 'timeFrame': 'Up to approximately 6 months2 years', 'description': 'Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)'}, {'measure': 'Time to Progression (TTP)', 'timeFrame': 'Up to approximately 2 years', 'description': 'Time to Progression (TTP) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)'}, {'measure': 'Overall Survival', 'timeFrame': 'Up to approximately 2 years', 'description': 'Overal Survial will be calculated based on Kaplan-Meier estimates'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Advanced Primary Liver Cancer', 'Advanced Biliary Tract Carcinoma']}, 'referencesModule': {'references': [{'pmid': '34309846', 'type': 'DERIVED', 'citation': 'Chen X, Qin S, Gu S, Ren Z, Chen Z, Xiong J, Liu Y, Meng Z, Zhang X, Wang L, Zhang X, Zou J. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. Int J Cancer. 2021 Dec 1;149(11):1944-1954. doi: 10.1002/ijc.33751. Epub 2021 Sep 8.'}, {'pmid': '33741732', 'type': 'DERIVED', 'citation': 'Mei K, Qin S, Chen Z, Liu Y, Wang L, Zou J. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191. doi: 10.1136/jitc-2020-002191.'}]}, 'descriptionModule': {'briefSummary': 'This an open-label，Non-Randominzed Phase 2 study to evaluate the Safety and Tolerability of SHR-1210 in combination with Apatinib or chemotherapy (FOLFOX4 or GEMOX regimen) in subjects with Advanced PLC.or BTC Participants with advanced PLC who failed or intolerable to prior systemic therapy will be treated with SHR-1210 plus Apatinib; Participants with advanced PLC or BTC who have never received prior systemic therapy will be treated with SHR-1210 plus FOLFOX4 or GEMOX regimen.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': '1. Histologically confirmed advanced PLC or advanced BTC (including bile duct carcinoma and gallbladder carcinoma) ; not suitable to surgery or local regional treatment; with at least one measurable lesion per RECIST 1.1.\n2. Arm A:Failed or intolerable to at least one prior systemic treatment for advanced PLC. Arm B:No previous systemic treatment for advanced PLC or BTC\n3. ECOG Performance Status of 0 or1.\n4. Child-Pugh Class A or B with 7 points .\n5. Life Expectancy of at least 12 weeks.\n6. Has controlled infection by Hepatitis B Virus (HBV DNA\\<500 IU/ml) or Hepatitis C Virus.\n7. Adequate organ function.\n8. Male or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 60 days for female subjects and 120 days for male subjects after the last dose of study drug.\n9. Patient has given written informed consent.\n\nExclusion Criteria:\n\n1. Known fibrolamellar HCC; Prior malignancy active with the previous 5 years except for locally curable cancers that have been apparently cured.\n2. Known or occurrence of central nervous system (CNS) metastases.\n3. Ascites with clinical symptoms.\n4. Known or evidence of GI hemorrhage within the past 6 months.\n5. Known or occurrence of hemorrhage/ thrombus.\n6. Known or evidence of abdomen fistula, gastrointestinal perforation, or abdominal abscess within the past 2 months.\n7. Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias.\n8. Grade III\\~IV cardiac insufficiency, according to NYHA criteria or echocardiography check: LVEF\\<50%.\n9. Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure \\> 140mmHg, diastolic blood pressure \\> 90 mmHg).\n10. Factors to affect oral administration (such as patients unable to swallow oral medications, chronic diarrhea and ileus etc. situations evidently affect drug oral medication and absorption).\n11. History of hepatic encephalopathy.\n12. Known history of human immunodeficiency virus (HIV) infection.\n13. Active infection or an unexplained fever \\> 38.5°C during screening visits.\n14. Has received a live vaccine within 30 days.\n15. Prior or planning to organ transplantation including liver transplantation.\n16. Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity.\n17. Proteinuria≥ 2+ or 24 hours total urine protein \\> 1.0 g.\n18. Active known, or suspected autoimmune disease.\n19. Subjects with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses \\> 10 mg daily. prednisone equivalent, are permitted in the absence of active autoimmune disease\n20. Any loco-regional therapy to liver (included but not limited: resection, radiotherapy, TAE, TACE, TAI, RFA or PEI) within 4 weeks prior to study.\n21. Prior therapy with anti-PD-1 or other anti-PD-1/anti-PD-L1 immunotherapy.\n22. Known history of hypersensitivity to monoclonal antibodies or any components of the study drugs.\n23. Treatment with anti-coagulation therapy(Warfarin or heparin) or anti-platelet therapy(aspirin at dose≥300mg/day, clopidogrel at dose≥75mg/day).\n24. Pregnant or breast-feeding women.\n25. According to the investigator, other conditions that may lead to stop the research.'}, 'identificationModule': {'nctId': 'NCT03092895', 'briefTitle': 'A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC', 'organization': {'class': 'INDUSTRY', 'fullName': 'Jiangsu HengRui Medicine Co., Ltd.'}, 'officialTitle': 'A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver Cancer（PLC）or Biliary Tract Carcinoma (BTC)', 'orgStudyIdInfo': {'id': 'SHR-1210-APTN-II-203-PLC'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'SHR-1210+Apatinib(Arm A）', 'interventionNames': ['Biological: SHR-1210', 'Drug: Apatinib']}, {'type': 'EXPERIMENTAL', 'label': 'SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）', 'interventionNames': ['Biological: SHR-1210', 'Drug: FOLFOX4', 'Drug: GEMOX']}], 'interventions': [{'name': 'SHR-1210', 'type': 'BIOLOGICAL', 'description': 'Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks', 'armGroupLabels': ['SHR-1210+Apatinib(Arm A）', 'SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）']}, {'name': 'Apatinib', 'type': 'DRUG', 'description': 'Subjects receive Apatinib orally every day with a dose escalation', 'armGroupLabels': ['SHR-1210+Apatinib(Arm A）']}, {'name': 'FOLFOX4', 'type': 'DRUG', 'description': 'Subjects receive FOLFOX4 treatment every 2 weeks', 'armGroupLabels': ['SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）']}, {'name': 'GEMOX', 'type': 'DRUG', 'description': 'Subjects receive GEMOX treatment every 2 weeks', 'armGroupLabels': ['SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）']}]}, 'contactsLocationsModule': {'locations': [{'zip': '230000', 'city': 'Hefei', 'state': 'Anhui', 'country': 'China', 'facility': 'The Second Affiliated Hospital Of Anhui Medical University', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'zip': '410000', 'city': 'Hunan', 'state': 'Changsha', 'country': 'China', 'facility': 'Hunan Cancer Hospital', 'geoPoint': {'lat': 28.71667, 'lon': 118.83333}}, {'zip': '450008', 'city': 'Zhengzhou', 'state': 'Henan', 'country': 'China', 'facility': 'Cancer Hospital of Henan province', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '210002', 'city': 'Nanjing', 'state': 'Jiangsu', 'country': 'China', 'facility': '81 Hospital Nanjing', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'zip': '330006', 'city': 'Jiangxi', 'state': 'Nanchang', 'country': 'China', 'facility': 'The First Affiliated Hospital of Nanchang University', 'geoPoint': {'lat': 33.99934, 'lon': 105.19994}}, {'zip': '200003', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'country': 'China', 'facility': 'Zhongshan Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '200032', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'country': 'China', 'facility': 'Fudan University Shanghai Cancer Center', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Jiangsu HengRui Medicine Co., Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}, 'annotationSection': {'annotationModule': {'unpostedAnnotation': {'unpostedEvents': [{'date': '2023-07-04', 'type': 'RELEASE'}, {'date': '2024-02-16', 'type': 'RESET'}, {'date': '2024-03-22', 'type': 'RELEASE'}, {'date': '2024-08-16', 'type': 'RESET'}], 'unpostedResponsibleParty': 'Jiangsu HengRui Medicine Co., Ltd.'}}}}